09:56 AM EST - Fennec Pharmaceuticals Inc. : Announced it has completed its rolling submission of a New Drug Application to the U.S. Food and Drug Administration for PEDMARK™ (a unique formulation of sodium thiosulfate) for intravenous use and submitted a Marketing Authorization Application to the European Medicines Agency for sodium thiosulfate (tradename to be determined). The PEDMARK™ indication requested is for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to < 18 years of age with localized, non-metastatic, solid tumors. Fennec Pharmaceuticals Inc.
shares T.FRX are trading unchanged at $8.72.
